Stoke Therapeutics (NASDAQ:STOK) Upgraded to “Outperform” at TD Cowen

Stoke Therapeutics (NASDAQ:STOK) was upgraded by investment analysts at TD Cowen from a “market perform” rating to an “outperform” rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports.

Several other equities research analysts also recently issued reports on STOK. Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 price target on shares of Stoke Therapeutics in a research report on Friday, February 16th. Canaccord Genuity Group raised their price target on Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. raised their price target on Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research report on Tuesday. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.63.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK opened at $14.17 on Tuesday. The company has a market cap of $632.69 million, a P/E ratio of -5.98 and a beta of 0.68. The stock’s 50-day moving average is $5.88 and its 200-day moving average is $4.95. Stoke Therapeutics has a 52-week low of $3.35 and a 52-week high of $16.40.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 11,150 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $68,015.00. Following the completion of the transaction, the chief executive officer now owns 69,350 shares in the company, valued at $423,035. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Stoke Therapeutics news, CFO Stephen J. Tulipano sold 4,116 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the transaction, the chief financial officer now owns 20,746 shares in the company, valued at $126,550.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Edward M. Md Kaye sold 11,150 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $68,015.00. Following the transaction, the chief executive officer now owns 69,350 shares of the company’s stock, valued at approximately $423,035. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 37,615 shares of company stock worth $212,852. Company insiders own 12.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. GSA Capital Partners LLP raised its stake in shares of Stoke Therapeutics by 514.7% in the third quarter. GSA Capital Partners LLP now owns 348,069 shares of the company’s stock valued at $1,371,000 after acquiring an additional 291,443 shares during the last quarter. Trexquant Investment LP increased its holdings in shares of Stoke Therapeutics by 166.9% in the third quarter. Trexquant Investment LP now owns 127,581 shares of the company’s stock valued at $503,000 after purchasing an additional 79,785 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in shares of Stoke Therapeutics in the second quarter valued at approximately $121,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Stoke Therapeutics by 9.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 146,076 shares of the company’s stock valued at $576,000 after purchasing an additional 12,478 shares in the last quarter. Finally, Corton Capital Inc. acquired a new stake in shares of Stoke Therapeutics in the third quarter valued at approximately $58,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.